Dong-A Socio's Unit Secures KRW91.3 Billion Oligonucleotide API Supply Contract
MT Newswires Live
Sep 21
ST Pharm, a subsidiary of Dong-A Socio (KRX:000640), has secured a purchase order contract to supply oligonucleotide API to a U.S.-based biotech company for 91.3 billion won.
The contract value represents 27.5% of ST Pharm's latest fiscal year consolidated sales of 331.7 billion won, according to a bourse filing on Monday.
The contract period runs from Sept. 18, 2026, to Nov. 22, 2027, with sales territories covering the U.S. and Europe, and production to be handled in-house.
The contract terms are subject to change at the counterparty's request, and details are being kept confidential at the client's request until Nov. 22, 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.